The study of interactions among IgA1-glycosylating enzymes in IgA nephropathy
Public support
Provider
Ministry of Education, Youth and Sports
Programme
KONTAKT II
Call for proposals
KONTAKT II 1 (SMSM2011LH1)
Main participants
—
Contest type
VS - Public tender
Contract ID
MSMT-6784/2013-311
Alternative language
Project name in Czech
Studium vztahů mezi enzymy glykosylujícími IgA1 imunoglobulin u IgA nefropatie
Annotation in Czech
Abnormality v O glykosylaci imunoglobulinu A1 (IgA1) patří mezi základní příčiny IgA nefropatie. Několik enzymů-glykosyltransferáz (GT), zejména ST6GalNAcII, C1GalT1, C1GalT2 a GalNAcT2 se uplatňuje při O-glykosylaci IgA1, která probíhá v Golgiho komplexu postupným, prostorově precizně organizovaným procesem. U B lymfoblastů produkujících abnormálně O-glykosylované IgA1 byla prokázána zvýšená exprese ST6GalNAcII a snížená exprese C1GalT1. Předpokládáme, že abnormality v koncentraci GT a jejich distribuci přispívají významně k abnormalitám v glykosylaci IgA1. První cíl projektu je lokalizace GT zapojených do glykosylace IgA1 u klonů B lymfoblastů izolovaných od pacientů s IgA nefropatií a od zdravých kontrol umožňující porovnat distribuci GT v Golgiho komplexu. Druhý cíl je zhodnotit změny distribuce GT po potlačení exprese jednotlivých GT siRNA a vyhodnotit příčinnou souvislost mezi abnormitami v koncentraci a distribuci GT v Golgiho komplexu IgA1 produkujících buněk.
Scientific branches
R&D category
ZV - Basic research
CEP classification - main branch
EC - Immunology
CEP - secondary branch
EB - Genetics and molecular biology
CEP - another secondary branch
EI - Biotechnology and bionics
OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)
10603 - Genetics and heredity (medical genetics to be 3)<br>10604 - Reproductive biology (medical aspects to be 3)<br>10605 - Developmental biology<br>10608 - Biochemistry and molecular biology<br>10609 - Biochemical research methods<br>20801 - Environmental biotechnology<br>20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management<br>20803 - Environmental biotechnology related ethics<br>20901 - Industrial biotechnology<br>20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation<br>20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials<br>30101 - Human genetics<br>30102 - Immunology<br>30401 - Health-related biotechnology<br>30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)<br>30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])<br>30404 - Biomaterials (as related to medical implants, devices, sensors)<br>30405 - Medical biotechnology related ethics<br>40401 - Agricultural biotechnology and food biotechnology<br>40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming<br>40403 - Agricultural biotechnology related ethics
Completed project evaluation
Provider evaluation
V - Vynikající výsledky projektu (s mezinárodním významem atd.)
Project results evaluation
"Using immunomicroscopy, abnormal distribution of sialyltransferase ST6GalNAc-II within Golgi apparatus of IgA1-producing cells from IgA nephropathy patients was identified. Using siRNA and enzymatic assays, direct involvement of ST6GalNAc-II, C1GalT1, GalNAc-T14, STAT3 in the production of aberrantly galactosylated IgA1 was confirmed. Results were published in 6 papers in journal with IF."
Solution timeline
Realization period - beginning
Mar 1, 2011
Realization period - end
Dec 31, 2014
Project status
U - Finished project
Latest support payment
Mar 3, 2014
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP15-MSM-LH-U/01:1
Data delivery date
Jul 2, 2015
Finance
Total approved costs
1,822 thou. CZK
Public financial support
1,822 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
0 thou. CZK